The prevalence, risk factors, and long-term outcome of vigabatrin-associated visual field defects were examined in 60 adult patients with partial epilepsy treated with vigabatrin for 7 months to 14 years at the University of Kuopio Hospital, Finland
PURPOSE: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. Th...
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia betw...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB). ...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractor...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
The magnitude of risk of vigabatrin-associated visual field loss and any clinical predictors of risk...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory e...
A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 c...
Visual deficits have been reported in retrospective, cross-sectional studies in vigabatrin-treated p...
Vigabatrin was introduced as an anti-seizure medication in the United Kingdom in 1989 and was extens...
Aim-To study the long term changes in the concentric contraction of the visual field in patients wit...
PURPOSE: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. Th...
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia betw...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB). ...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractor...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
The magnitude of risk of vigabatrin-associated visual field loss and any clinical predictors of risk...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory e...
A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 c...
Visual deficits have been reported in retrospective, cross-sectional studies in vigabatrin-treated p...
Vigabatrin was introduced as an anti-seizure medication in the United Kingdom in 1989 and was extens...
Aim-To study the long term changes in the concentric contraction of the visual field in patients wit...
PURPOSE: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. Th...
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia betw...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
DOI
Add to ORKG